Monthly Archives: May 2017

Page 4 of 41234

This is demonstrated by the analysis of the info from secondary clinical research endpoints.

Alzheimer’s vaccine – First proof for efficacy AFFiRiS’ Alzheimer’s vaccine applicant AD02 showed indicative evidence for potential efficacy in a phase I actually clinical trial. This is demonstrated by the analysis of the info from secondary clinical research endpoints nolvadex-d.net/nolvadex-safety-concerns.htm read more . AFFiRiS AG previously announced that their Alzheimer vaccine candidate Advertisement02 met the principal endpoints of stage I clinical screening by demonstrating security and tolerability. 24 subjects had been vaccinated, 12 received the vaccine with adjuvant and 12 without. Continue reading

Page 4 of 41234